Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN SULFATE versus GVS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN SULFATE versus GVS.
GENTAMICIN SULFATE vs GVS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
GVS is not a recognized drug. No mechanism of action available.
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic